Fintel reports that on April 13, 2026, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 641.98% Upside As of April 9, ...
Fintel reports that on April 13, 2026, Jefferies downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Buy to Hold. Analyst Price Forecast Suggests 641.98% Upside As of April 9, 2026, the ...
Like many silly gamers yesterday, April Fools ‘ Day came and offered players many memes. Discord was not about to miss out on that feature and dropped a sort of browser-like MMO game within the ...
©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...
Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...